Digital Biotechnology Lab
We are passionate about harnessing the power of modern technology to innovate the biotechnological landscape and develop real world solutions for the benefit of society. We focus on leveraging the power of data science, AI, and automation to discover and understand protein-protein interactions with a particular focus on binders, such as antibodies, nanobodies, and minibinders. Specifically, we are interested in (1) building de novo peptide sequencing solutions such as InstaNovo to identify key protein targets, as well as (2) the discovery, AI-design, and engineering of binding proteins. Importantly, this not only allows us to pursue fundamental questions, such as unravelling the core rule set that dictates binder-target interactions and poly- vs mono-specificity, but also translational endeavours, such as discovering cost-effective reagents, diagnostics, and therapeutics within a plethora of areas including toxins, cancer, viral infections, allergy, and bioindustrials.
Our mission is to leverage modern technology to drive innovation in biotechnology and deliver impactful solutions for society.
We specialize in using data science, AI, and automation to uncover and understand protein-protein interactions, focusing on binders like antibodies, nanobodies, and minibinders. Our key areas of interest include:
- De novo peptide sequencing—developing solutions like InstaNovo to identify crucial protein targets.
- Binder discovery and engineering—employing AI for the design and optimization of binding proteins.
Our work bridges fundamental research and real-world applications. We aim to unravel the rules governing binder-target interactions, such as poly- vs mono-specificity, while pursuing translational efforts like creating cost-effective reagents, diagnostics, and therapeutics. These solutions address challenges across diverse fields, including toxin neutralization, cancer, viral infections, allergy, and bioindustrials.